Welcome to our dedicated page for SCII Acquisition II news (Ticker: SCIIU), a resource for investors and traders seeking the latest updates and insights on SCII Acquisition II stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SCII Acquisition II's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SCII Acquisition II's position in the market.
SC II Acquisition Corp (NASDAQ: SCIIU) closed its initial public offering on November 28, 2025, selling 17,250,000 units at $10.00 per unit for $172,500,000 gross proceeds, which includes 2,250,000 overallotment units exercised in full. Units began trading on Nasdaq on November 26, 2025 under the symbol SCIIU. Each unit contains one Class A ordinary share and one right to receive 1/5 of a Class A share upon consummation of an initial business combination; Class A shares and rights are expected to trade separately as SCII and SCIIR.
A concurrent private placement sold 255,000 units at $10.00 for $2,550,000. The sponsor is managed by Nukkleus Defense Technologies, a subsidiary of Nukkleus (Nasdaq: NUKK). D. Boral Capital acted as book-runner.
SC II Acquisition Corp (NASDAQ: SCIIU) priced an initial public offering of 15,000,000 units at $10.00 per unit, implying gross proceeds of $150,000,000. Units will begin trading on November 26, 2025 and closing is expected on November 28, 2025, subject to customary closing conditions.
Each unit contains one Class A ordinary share and one right to receive 1/5 of a Class A share upon consummation of an initial business combination. The underwriters have a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. The sponsor is managed by Nukkleus (Nasdaq: NUKK).
FAQ
What is the current stock price of SCII Acquisition II (SCIIU)?
